Loading...
Loading...
India's pomalidomide imports from ISRAEL total $33.8K across 2 shipments from 1 foreign suppliers. TEVA PHARMACEUTICAL INDUSTRIES LTD leads with $33.8K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include WATSON PHARMA PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for pomalidomide โ a concentrated sourcing relationship with select suppliers from ISRAEL.

TEVA PHARMACEUTICAL INDUSTRIES LTD is the leading Pomalidomide supplier from ISRAEL to India, with import value of $33.8K across 2 shipments. The top 5 suppliers โ TEVA PHARMACEUTICAL INDUSTRIES LTD โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | TEVA PHARMACEUTICAL INDUSTRIES LTD | $33.8K | 2 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | WATSON PHARMA PRIVATE LIMITED | $33.8K | 2 | 100.0% |
ISRAEL โ India trade corridor intelligence
The Israel to India trade corridor for pharmaceutical imports is currently stable, with no significant disruptions reported. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with minimal congestion affecting pharmaceutical shipments. Freight rates have remained consistent over the past year, and the exchange rate between the Israeli New Shekel (ILS) and the Indian Rupee (INR) has shown moderate fluctuations, not significantly impacting the cost-effectiveness of imports. Importers should continue to monitor these factors to ensure timely and cost-effective procurement of Pomalidomide formulations from Israel.
India's Production Linked Incentive (PLI) scheme, introduced to boost domestic manufacturing, may influence the import dynamics of pharmaceutical formulations, including Pomalidomide. While the PLI scheme primarily targets domestic production, it could lead to a reduction in import dependency over time as domestic manufacturers scale up their capabilities. However, the immediate impact on imports from Israel is expected to be minimal, as the demand for specialized formulations like Pomalidomide remains high. Importers should stay informed about policy changes and assess their sourcing strategies accordingly.
The trade relationship between India and Israel is robust, characterized by cooperation in various sectors, including pharmaceuticals. Both countries have engaged in discussions to facilitate trade, streamline regulatory processes, and enhance mutual recognition of Good Manufacturing Practices (GMP). These efforts aim to simplify the importation of pharmaceutical products, such as Pomalidomide formulations, and ensure compliance with international standards. Ongoing dialogues and agreements continue to strengthen bilateral trade relations, benefiting stakeholders in both nations.
To estimate the landed cost of importing Pomalidomide formulations from Israel to India, consider the following components:
By summing these components, importers can calculate the total landed cost per unit of Pomalidomide formulations imported from Israel.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Pomalidomide into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs be registered and approved before distribution. The registration process involves obtaining a Registration Certificate (Form 41) from CDSCO, which certifies the drug's safety, efficacy, and quality. An Import License is also required, issued by the Directorate General of Foreign Trade (DGFT), permitting the importation of the drug. The application for registration must include comprehensive documentation, such as the Certificate of Pharmaceutical Product (CoPP), stability data (preferably ICH Zone IV), and a No Objection Certificate (NOC) from the manufacturer. The timeline for obtaining these approvals can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory review process.
Imported pharmaceutical formulations are subject to quality testing by CDSCO-approved laboratories to ensure compliance with Indian Pharmacopoeia standards. Each batch of the imported product must be accompanied by a Certificate of Analysis (CoA) from the manufacturer, detailing the product's composition, quality control measures, and compliance with specified standards. Stability data, particularly for ICH Zone IV conditions, is essential to demonstrate the product's shelf-life and storage requirements. Upon arrival at Indian ports, customs drug inspectors conduct inspections to verify the authenticity of the documentation and the quality of the product. If a batch fails to meet the required standards, it may be rejected, re-exported, or destroyed, depending on the severity of the non-compliance.
Between 2024 and 2026, the CDSCO has implemented stricter regulations for the importation of pharmaceutical products to enhance drug safety and efficacy. Notably, on April 8, 2025, the CDSCO mandated that all imported drugs, including finished formulations, must obtain both import registration and an import license before distribution in India. This directive aims to prevent the sale of unapproved or illegal medicines in the Indian market. Additionally, the introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially affecting the demand for imported formulations. While the PLI scheme primarily targets domestic production, it may influence import patterns as companies assess the cost-effectiveness of sourcing domestically versus importing.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Pomalidomide formulations to meet the therapeutic needs of patients, particularly those requiring specialized dosage forms not readily available domestically. The domestic production of Pomalidomide formulations may be limited due to patent protections, technological constraints, or economic considerations. The market size for Pomalidomide formulations in India is substantial, with imports totaling approximately $4.4 million across 108 exporters to 52 countries. This indicates a significant demand for Pomalidomide formulations, driven by the need for effective treatments in oncology and related fields.
The import duty structure for finished pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Integrated Goods and Services Tax (IGST) of 12%, and a Social Welfare Surcharge (SWS) of 10% on the BCD. This results in a total landed duty of approximately 23.6%. There are no specific exemptions or concessional duties for imports from Israel under this HS code. Importers should account for these duties when calculating the total cost of importing Pomalidomide formulations from Israel.
Israel's pharmaceutical industry is renowned for its high-quality standards, innovative formulations, and adherence to international regulatory requirements. Indian importers source Pomalidomide formulations from Israel due to these competitive advantages, as well as the availability of specialized dosage forms and formulations that may not be produced domestically. While other countries, such as China, Germany, and the United States, also supply Pomalidomide formulations, Israel's reputation for quality and reliability positions it favorably in the Indian market. Israel's share in India's Pomalidomide import market is notable, reflecting the trust and preference Indian buyers have for Israeli pharmaceutical products.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Pomalidomide formulations from Israel due to the country's advanced pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized formulations not produced domestically. Israeli manufacturers offer innovative dosage forms and formulations that cater to specific therapeutic needs, ensuring efficacy and safety. The trust in Israeli pharmaceutical products is bolstered by the country's robust regulatory framework and consistent product quality.
When compared to other sources such as China, Germany, and the United States, Israel offers a competitive edge in terms of product quality, regulatory compliance, and innovation. Israeli pharmaceutical products are known for their high standards and reliability, which are crucial for the Indian market's stringent requirements. While other countries may offer cost advantages, Israel's reputation for quality and consistency makes it a preferred choice for importing Pomalidomide formulations.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Pomalidomide suppliers from ISRAEL to India include TEVA PHARMACEUTICAL INDUSTRIES LTD. The leading supplier is TEVA PHARMACEUTICAL INDUSTRIES LTD with import value of $33.8K USD across 2 shipments. India imported Pomalidomide worth $33.8K USD from ISRAEL in total across 2 shipments.
India imported Pomalidomide worth $33.8K USD from ISRAEL across 2 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Pomalidomide sourced from ISRAEL include WATSON PHARMA PRIVATE LIMITED. The largest buyer is WATSON PHARMA PRIVATE LIMITED with $33.8K in imports across 2 shipments.
The total value of Pomalidomide imports from ISRAEL to India is $33.8K USD, across 2 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists